ASH 2021 | Interim analysis of the LOTIS-3 trial
Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, provides an overview of the interim analysis of the open-label, Phase II LOTIS-3 trial (NCT03684694) investigating loncastuximab tesirine plus ibrutinib in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Out of the 35 patients were enrolled, 13 and 22 patients were diagnosed with the germinal center B-cell like (GCB) subtype, and non-GCB DLBCL respectively. Loncastuximab tesirine demonstrated promising activity and had an acceptable safety profile, with the complete response rate (CRR) being 34.3% in the overall DLBCL cohort. However, duration of response was not reached in the cohort.. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
